Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

August 17, 2018 3:14 AM UTC

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said RXI-109 was well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported in the Phase I/II RXI-109-1501 trial in nine patients with advanced neovascular age-related macular degeneration (AMD) and accompanying subretinal fibrosis.

Patients in the open-label, U.S. trial received four intravitreal injections of RXI-109 into one eye only at monthly intervals, followed by an observation period of four months...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article